CARL

시간 외 거래: 12.59 -0.15 -1.18%

Carlsmed Inc (CARL)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Carlsmed Inc Stock (CARL) Company Profile

Carlsmed Inc

Healthcare (1149)

858-295-9290

1800 ASTON AVENUE, CARLSBAD

최신 SEC 제출 서류

CARL's Discussions on Twitter

CARL을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CARL Carlsmed Inc	12.74	343.16M	0	0	0	0.00
VEEV Veeva Systems Inc	272.93	44.26B	2.97B	809.93M	1.33B	4.87
TEM Tempus Ai Inc	79.62	13.57B	803.32M	-709.10M	-212.68M	-7.8003
DOCS Doximity Inc	69.34	12.83B	550.17M	201.35M	232.07M	1.00
HQY Healthequity Inc	91.48	8.42B	1.15B	96.70M	-161.99M	1.09
WAY Waystar Holding Corp	37.27	6.49B	906.14M	-52.62M	89.62M	-0.3621

Carlsmed Inc Stock (CARL) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-08-18	개시	BTIG Research	Buy
2025-08-18	개시	BofA Securities	Buy
2025-08-18	개시	Goldman	Buy
2025-08-18	개시	Piper Sandler	Overweight
2025-08-18	개시	Truist	Buy

Carlsmed Inc 주식(CARL)의 최신 뉴스

Carlsmed Inc (CARL) 재무 분석

Carlsmed Inc (CARL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Carlsmed Inc 주식 (CARL) 내부자 거래

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
Sidow Kevin	Director	Jul 24 '25	Buy	15.00	13,333	199,995	59,566
Mittendorff Robert II	Director	Jul 24 '25	Buy	15.00	1,333,333	19,999,995	5,013,839
ROOT JONATHAN D	Director	Jul 24 '25	Buy	15.00	466,666	6,999,990	483,999
YOUNG PHILIP M	Director	Jul 24 '25	Buy	15.00	59,999	899,985	53,333

Carlsmed Inc (CARL)

Carlsmed Inc Stock (CARL) Company Profile

CARL을(를) 다른 주식과 비교

Carlsmed Inc Stock (CARL) Upgrades & Downgrades

Carlsmed Inc 주식(CARL)의 최신 뉴스

Carlsmed initiated with Buy at Truist on business potential - MSN

Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer

Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks

Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com

Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks

Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks

Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest

Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest

UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times

Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com

Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener

Carlsmed reports second quarter 2025 financial results - MarketScreener

Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest

CARLSMED, INC. SEC 10-Q Report - TradingView

Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest

Carlsmed® Reports Second Quarter 2025 Financial Results - MarketScreener

99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan

Carlsmed CARL 2025Q2 Earnings Preview Upside Potential on AI-Driven Spine Solutions - AInvest

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Truist Securities initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Australia

Why Is Carlsmed Stock Gaining Monday?Carlsmed (NASDAQ:CARL) - Benzinga

AI medtech firm Carlsmed prices $100.5M IPO - MSN

Truist Initiates Buy on Carlsmed with Focus on Business Growth Potential - AInvest

Carlsmed initiated with Buy at Truist on business potential (CARL) - Seeking Alpha

BofA Securities Initiates Coverage on Carlsmed With Buy Rating, $16 Price Target - MarketScreener

This Synaptics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Goldman Sachs Initiates Coverage on Carlsmed With Buy Rating, $19 Price Target - MarketScreener

Carlsmed initiated with a Buy at BTIG - TipRanks

Truist Securities initiates coverage on Carlsmed stock with Buy rating - Investing.com

Truist Initiates Carlsmed at Buy With $18 Price Target - MarketScreener

Piper Sandler initiates coverage on Carlsmed with an Overweight rating, PT of $18. - AInvest

Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation - TipRanks

Carlsmed stock initiated with Buy rating at BTIG on customized implant tech - Investing.com

Carlsmed stock initiated with Buy rating at BTIG on customized implant tech By Investing.com - Investing.com South Africa

Carlsmed initiated with an Overweight at Piper Sandler - TipRanks

Piper Sandler initiates Carlsmed stock with Overweight rating on custom implant potential - Investing.com India

Goldman Sachs initiates coverage on Carlsmed stock with Buy rating - Investing.com

Goldman Sachs initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Nigeria

Carlsmed initiated with a Buy at Goldman Sachs - MSN

Carlsmed Stock Down 6% Since IPO But Goldman Bullish And Predicts 35% Upside Potential — Retail Traders Stay Bearish - Stocktwits

AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN

Carlsmed, Inc. shares fall 2.01% after-hours as it prepares to report Q2 2025 financial results. - AInvest

Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025 - The Manila Times

Carlsmed to report Q2 2025 financial results on Aug 28, 2025. - AInvest

Big Boost for Personalized Cervical Fusion: Add-On Code - Orthopedics This Week

Heartflow raises $317M, pops 66% at market open - BioWorld MedTech

Med-tech funding rebounds modestly to $18B through July - BioWorld MedTech

Carlsmed’s $100.5M IPO fuels 3D printed spinal implants growth - 3D Printing Industry

Carlsmed’s aprevo implants receive CMS NTAP for cervical fusion procedures - TipRanks

Carlsmed’s aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures - Ortho Spine News

Carlsmed's Aprevo Implants Receive CMS NTAP Approval For Cervical Fusion Procedures Under FY2026 IPPS Final Rule - 富途牛牛

Carlsmed Inc (CARL) 재무 분석

매출

순이익

현금흐름

주당 순 이익

Carlsmed Inc 주식 (CARL) 내부자 거래

CARL과 유사한 종목